tumori gastrointestinali - aiom · colangiocarcinoma • claridhy ivosidenib vs placebo •...
TRANSCRIPT
![Page 1: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/1.jpg)
TUMORI GASTROINTESTINALI
Antonia Strippoli
Nuove Prospettive: tumori NON colon-retto
![Page 2: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/2.jpg)
![Page 3: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/3.jpg)
Nuove Prospettive: tumori non COLON-RETTO
EPATOCARCINOMA • CHECKMATE 459 Nivolumab vs Sorafenib • GO30140 Bevacizumab +/- Atezolizumab COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab paclitaxel • NEOLAP gemcitabina+Nab paclitaxel vs FOLFIRINOX CARCINOMA GASTRICO LOCALIZZATO • PRODIGY chemioterapia peri-operatoria vs chemioterapia post-operatoria • RESOLVE SOX peri-operatorio vs CAPOX post-operatorio vs SOX post-op CARCINOMA ESOFAGO-GASTRICO METASTATICO • ATTRACTION 3 Nivolumab vs Taxani • KEYNOTE 062 MSI CT vs Pembrolizumab vs CT+Pembrolizumab • ANGEL Rivoceranib vs Placebo
![Page 4: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/4.jpg)
Nuove Prospettive: tumori non COLON-RETTO
EPATOCARCINOMA • CHECKMATE 459 Nivolumab vs Sorafenib • GO30140 Bevacizumab +/- Atezolizumab COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab paclitaxel • NEOLAP gemcitabina+Nab paclitaxel vs FOLFIRINOX CARCINOMA GASTRICO LOCALIZZATO • PRODIGY chemioterapia peri-operatoria vs chemioterpia post-operatoria • RESOLVE SOX peri-operatorio vs CAPOX post-operatorio vs SOX post-op CARCINOMA ESOFAGO-GASTRICO METASTATICO • ATTRACTION 3 Nivolumab vs Taxani • KEYNOTE 062 MSI CT vs Pembrolizumab vs CT+Pembrolizumab • ANGEL Rivoceranib vs Placebo
![Page 5: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/5.jpg)
Epatocarcinoma: ESMO clinical Practice Guidelines for diagnosis, treatment and Follow up
![Page 6: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/6.jpg)
CHECKMATE 459: FIRST LINE PHASE III RCT OF NIVOLUMAB VS SORAFENIB IN ADVANCED HCC
Primary endpoint: OS Yau et al ESMO 2019
Niv Sor CR 4% 1% PR 12% 6% OR: 2.41 (95% CI: 1.48, 3.92)
![Page 7: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/7.jpg)
CHECKMATE 459: TREATMENT EFFECT IN PREDEFINED
SUBSETS
![Page 8: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/8.jpg)
PHASE Ib GO30140
![Page 9: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/9.jpg)
PHASE Ib GO30140: EFFICACY
![Page 10: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/10.jpg)
GO30140 ARM F primary
Endpoint: PFSa
![Page 11: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/11.jpg)
Nuove Prospettive: tumori non COLON-RETTO
EPATOCARCINOMA • CHECKMATE 459 Nivolumab vs Sorafenib • GO30140 Bevacizumab +/- Atezolizumab COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab paclitaxel • NEOLAP gemcitabina+Nab paclitaxel vs FOLFIRINOX CARCINOMA GASTRICO LOCALIZZATO • PRODIGY chemioterapia peri-operatoria vs chemioterpia post-operatoria • RESOLVE SOX peri-operatorio vs CAPOX post-operatorio vs SOX post-op CARCINOMA ESOFAGO-GASTRICO METASTATICO • ATTRACTION 3 Nivolumab vs Taxani • KEYNOTE 062 MSI CT vs Pembrolizumab vs CT+Pembrolizumab • ANGEL Rivoceranib vs Placebo
![Page 12: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/12.jpg)
ESMO guidelines for biliary tract cancer management
![Page 13: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/13.jpg)
Randomized second line phase III study of FOLFOX vs active symptom control in advanced biliary tract cancer
![Page 14: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/14.jpg)
ESMO guidelines for biliary tract cancer management
![Page 15: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/15.jpg)
Integrated genomic and epigenomic characterisation of biliary tract cancer (BTC)
![Page 16: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/16.jpg)
IDH1 mutations in cholangiocarcinoma Systematic Review
![Page 17: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/17.jpg)
ClarIDHdy: phase III study of Ivosidenib vs placebo in advanced mIDH1 biliary tract cancer
Abou-Alfa et al, ESMO 2019
![Page 18: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/18.jpg)
ClarIDHdy: Overall Survival
Abou-Alfa et al, ESMO 2019
![Page 19: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/19.jpg)
Targeted therapy in molecularly-altereted
advanced cholangiocarcinoma
![Page 20: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/20.jpg)
FIGHT 202
Vogel et al, ESMO 2019
![Page 21: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/21.jpg)
FIGHT 202
Vogel et al, ESMO 2019
![Page 22: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/22.jpg)
FIGHT 202: response
Vogel et al, ESMO 2019
![Page 23: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/23.jpg)
FIGHT: OS e PFS
Vogel et al, ESMO 2019
![Page 24: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/24.jpg)
Nuove Prospettive: tumori non COLON-RETTO
EPATOCARCINOMA • CHECKMATE 459 Nivolumab vs Sorafenib • GO30140 Bevacizumab +/- Atezolizumab COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab paclitaxel • NEOLAP gemcitabina+Nab paclitaxel vs FOLFIRINOX CARCINOMA GASTRICO LOCALIZZATO • PRODIGY chemioterapia peri-operatoria vs chemioterpia post-operatoria • RESOLVE SOX peri-operatorio vs CAPOX post-operatorio vs SOX post-op CARCINOMA ESOFAGO-GASTRICO METASTATICO • ATTRACTION 3 Nivolumab vs Taxani • KEYNOTE 062 MSI CT vs Pembrolizumab vs CT+Pembrolizumab • ANGEL Rivoceranib vs Placebo
![Page 25: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/25.jpg)
GAP and NEOLAP in locally
advanced pancreatic cancer
![Page 26: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/26.jpg)
GAP and NEOLAP in locally
advanced pancreatic cancer
![Page 27: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/27.jpg)
NEOLAP Overall Survival
![Page 28: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/28.jpg)
Nuove Prospettive: tumori non COLON-RETTO
EPATOCARCINOMA • CHECKMATE 459 Nivolumab vs Sorafenib • GO30140 Bevacizumab +/- Atezolizumab COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab paclitaxel • NEOLAP gemcitabina+Nab paclitaxel vs FOLFIRINOX CARCINOMA GASTRICO LOCALIZZATO • PRODIGY chemioterapia peri-operatoria vs chemioterpia post-operatoria • RESOLVE SOX peri-operatorio vs CAPOX post-operatorio vs SOX post-op CARCINOMA ESOFAGO-GASTRICO METASTATICO • ATTRACTION 3 Nivolumab vs Taxani • KEYNOTE 062 MSI CT vs Pembrolizumab vs CT+Pembrolizumab • ANGEL Rivoceranib vs Placebo
![Page 29: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/29.jpg)
![Page 30: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/30.jpg)
PRODIGY: Randomised phase III study in
gastric and GEJ adenocarcinoma of peri-op
vs post-op chemotherapy
Primary endpoint: 3years PFS
![Page 31: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/31.jpg)
RESOLVE STUDY
![Page 32: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/32.jpg)
RESOLVE: Randomised phase III study in
gastric and GEJ adenocarcinoma of peri-op
SOX vs post-op SOX vs post-op CAPOX
![Page 33: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/33.jpg)
RESOLVE primary comparisons
![Page 34: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/34.jpg)
Nuove Prospettive: tumori non COLON-RETTO
EPATOCARCINOMA • CHECKMATE 459 Nivolumab vs Sorafenib • GO30140 Bevacizumab +/- Atezolizumab COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab paclitaxel • NEOLAP gemcitabina+Nab paclitaxel vs FOLFIRINOX CARCINOMA GASTRICO LOCALIZZATO • PRODIGY chemioterapia peri-operatoria vs chemioterpia post-operatoria • RESOLVE SOX peri-operatorio vs CAPOX post-operatorio vs SOX post-op CARCINOMA ESOFAGO-GASTRICO METASTATICO • ANGEL Rivoceranib vs Placebo • KEYNOTE 062 MSI CT vs Pembrolizumab vs CT+Pembrolizumab • ATTRACTION 3 Nivolumab vs Taxani
![Page 35: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/35.jpg)
Apatinib in gastric cancer
Kang et al, ESMO 2019
![Page 36: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/36.jpg)
Background
![Page 37: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/37.jpg)
ANGEL: a global randomized
phase III study
![Page 38: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/38.jpg)
ANGEL: OS
![Page 39: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/39.jpg)
ANGEL: OS and PFS in ≥ 4 line
patients
![Page 40: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/40.jpg)
Randomized first line phase III Pembrolizumab
study in gastric and GEJ adenocarcinoma
KEYNOTE-062 MSI subgroup
![Page 41: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/41.jpg)
Pembro vs CT: OS in ITT
![Page 42: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/42.jpg)
Pembro vs CT: OS in MSI-H group
![Page 43: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/43.jpg)
Pembro vs CT: PFS and DOR in
MSI-H group (CPS≥1)
![Page 44: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/44.jpg)
Pembro+CT vs Pembro: OS in MSI-H group
![Page 45: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/45.jpg)
ATTRACTION-3: Randomized second line
phase III study in squamous oesphageal
carcinoma (SCC) with Nivolumab
FIRST ENDPOINT: OS
Cho et al, ESMO 2019
![Page 46: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/46.jpg)
Treatment Paradigm in
advanced/metastatic SCC oesophagus
2019
Inoperable/metastatic/reccurrent SCC
Platinum+FP based CT
Nivolumab Pembrolizumab if PDL1 CPS>10
Taxanes or Irinotecan
![Page 47: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/47.jpg)
TUMORI GASTROINTESTINALI
Antonia Strippoli
Nuove Prospettive: tumori NON colon-retto
Grazie
![Page 48: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/48.jpg)
![Page 49: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/49.jpg)
![Page 50: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/50.jpg)
![Page 51: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/51.jpg)
![Page 52: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/52.jpg)
ClarIDHdy: phase III study of Ivosidenib vs placebo in advanced mIDH1 biliary tract cancer
Abou-Alfa et al, ESMO 2019
![Page 53: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/53.jpg)
FIGHT 202: AE
Vogel et al, ESMO 2019
![Page 54: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/54.jpg)
FIGHT 202: ORR
Vogel et al, ESMO 2019
![Page 55: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/55.jpg)
![Page 56: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/56.jpg)
Pembro vs CT: OS in non MSI-H group
![Page 57: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/57.jpg)
![Page 58: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/58.jpg)
![Page 59: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/59.jpg)
![Page 60: TUMORI GASTROINTESTINALI - AIOM · COLANGIOCARCINOMA • ClarIDHY Ivosidenib vs placebo • Pemigatinib CARCINOMA PANCREATICO LOCALMENTE AVANZATO • GAP gemcitabina vs gemcitabina+Nab](https://reader034.vdocuments.pub/reader034/viewer/2022043021/5f3cbb517afc0a255d69e55d/html5/thumbnails/60.jpg)